Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 76420-908

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 76420-908). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
The text provides information on the estimated probability of achieving an initial headache response within 2 hours based on pooled data from multiple studies evaluating rizatriptan benzoate compared to a placebo. The Kaplan-Meier plot displayed in Figure 1 shows the probability over time of obtaining headache response following treatment. The data is derived from 4 placebo-controlled outpatient trials (Studies 1, 2, 3, and 4) and includes patients who did not achieve headache response prior to 2 hours.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)
The text provides a graphical representation (Kaplan-Meier plot) showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate Tablets or other medication for migraines over the 24 hours following the initial dose of study treatment. The plot is based on data from four placebo-controlled outpatient clinical trials (Studies 1, 2, 3, and 4) and includes patients with both headache response at 2 hours and those with no response to the initial dose. It mentions that patients were not allowed to take additional treatments within 2 hours post-dose and those not using additional treatments were censored at 24 hours.*
FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)
The text provides a description of Figure 3, indicating that it shows the estimated probability of achieving an initial headache response with Rizatriptan Benzoate Orally Disintegrating Tablets within 2 hours in Pooled Studies 5 and 6. It mentions that the figure displays the Kaplan-Meier plot showing the probability over time of obtaining a headache response following treatment with the tablets or placebo. The data is based on two placebo-controlled outpatient trials (Studies 5 and 6). Patients who did not achieve a headache response within 2 hours were also considered.*
FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose O (Rizatriptan Fig4)

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose O (Rizatriptan Fig4)
The text provides a figure showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate Orally Disintegrating Tablets or other medication for migraines over the 24 hours following the initial dose of study treatment in pooled Studies 5 and 6. This data is presented as a Kaplan-Meier plot based on data obtained in two placebo-controlled outpatient clinical trials (Studies 3 and 6) where patients not using additional treatments were censored at 24 hours. The plot includes patients who had a headache response at 2 hours and those who had no response to the initial dose, with the goal of understanding the need for additional medication or rescue treatment.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)
This text presents a figure illustrating the observed percentage of patients reporting no headache pain by 2 hours post-dose in Study 7. The figure displays the data with percent values and confidence intervals for Rizatriptan Benzoate OD Tablets and Placebo. Time points and the corresponding percentages of patients reporting no headache pain are presented for both treatments. This data visualization provides insights into the effectiveness of the medication in relieving headache pain over time.*
FDA Label Image

5 mg (Rizatriptan Fig6)

5 mg (Rizatriptan Fig6)
FDA Label Image

10 mg (Rizatriptan Fig7)

10 mg (Rizatriptan Fig7)
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.